- Home
- HL vs ELAN Comparison
HL vs ELAN Comparison
Compare HL & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | ELAN |
|---|---|---|
| Founded | 1891 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 12.2B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HL | ELAN |
|---|---|---|
| Price | $15.26 | $23.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $22.78 | ★ $31.07 |
| AVG Volume (30 Days) | ★ 34.2M | 4.3M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 716.67 | N/A |
| EPS | 0.15 | ★ 0.22 |
| Revenue | $645,957,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | $29.59 | $5.47 |
| P/E Ratio | ★ $103.57 | $106.86 |
| Revenue Growth | ★ 45.63 | 6.22 |
| 52 Week Low | $11.81 | $19.40 |
| 52 Week High | $34.17 | $27.98 |
Technical Indicators
Market Signals| Indicator | HL | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 58.46 |
| Support Level | $13.98 | $23.04 |
| Resistance Level | $16.43 | $25.21 |
| Average True Range (ATR) | 0.58 | 0.64 |
| MACD | -0.19 | 0.18 |
| Stochastic Oscillator | 22.04 | 77.91 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.